These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 29188435)

  • 1. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
    Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
    Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
    Sapra P; Betts A; Boni J
    Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-drug conjugates: present and future.
    Beck A; Reichert JM
    MAbs; 2014; 6(1):15-7. PubMed ID: 24423577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index.
    Coats S; Williams M; Kebble B; Dixit R; Tseng L; Yao NS; Tice DA; Soria JC
    Clin Cancer Res; 2019 Sep; 25(18):5441-5448. PubMed ID: 30979742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
    Singh AP; Shah DK
    AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
    Lambert JM; Morris CQ
    Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug conjugates such as Antibody Drug Conjugates (ADCs), immunotoxins and immunoliposomes challenge daily clinical practice.
    Janthur WD; Cantoni N; Mamot C
    Int J Mol Sci; 2012 Nov; 13(12):16020-45. PubMed ID: 23443108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances of antibody drug conjugates for clinical applications.
    Zhao P; Zhang Y; Li W; Jeanty C; Xiang G; Dong Y
    Acta Pharm Sin B; 2020 Sep; 10(9):1589-1600. PubMed ID: 33088681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
    Cianfriglia M
    Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.
    Thudium K; Bilic S; Leipold D; Mallet W; Kaur S; Meibohm B; Erickson H; Tibbitts J; Zhao H; Gupta M
    MAbs; 2013; 5(1):5-12. PubMed ID: 23255090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enthusiasm for antibody-drug conjugates.
    Tuma RS
    J Natl Cancer Inst; 2011 Oct; 103(20):1493-4. PubMed ID: 21972230
    [No Abstract]   [Full Text] [Related]  

  • 16. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes.
    Abdollahpour-Alitappeh M; Lotfinia M; Gharibi T; Mardaneh J; Farhadihosseinabadi B; Larki P; Faghfourian B; Sepehr KS; Abbaszadeh-Goudarzi K; Abbaszadeh-Goudarzi G; Johari B; Zali MR; Bagheri N
    J Cell Physiol; 2019 May; 234(5):5628-5642. PubMed ID: 30478951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
    Corrigan PA; Cicci TA; Auten JJ; Lowe DK
    Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
    Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
    Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy.
    Cilliers C; Guo H; Liao J; Christodolu N; Thurber GM
    AAPS J; 2016 Sep; 18(5):1117-1130. PubMed ID: 27287046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.